Northstar Electronics, Inc.’s (NEIK) Progress Update

Vancouver, British Columbia-March 21, 2018 – Northstar Electronics, Inc. (OTCQB:NEIK) provides an updated report on its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL). NSEL continues to work diligently to acquire a “Definitive Agreement” for the worldwide rights to a “Turbo Prop” single engine industrial airplane from a world leader in the aerospace industry. The primary applications of the airplane are for “Agriculture” and “Rapid Response Forest Fire Fighting (RRFFF),” where the needs for both variants of the airplane are high. Management continues to interact weekly with senior managers in the international aerospace company and its subsidiary.

The Company believes the new design features of the NSEL “Agriculture and Rapid Response Forest Fire Fighting” airplanes will quickly lead to it being a leader in its class.
There is a strong possibility that the large aerospace company will use NSEL’s transaction as an “Offset,” which means that much of NSEL’s acquisition costs, including the “Intellectual Property (IP),” prototype, etc., would be covered by them. The valuation of the “Offset” is currently underway.

Cloud Seeding, using a variation of the RRFFF airplane, is being considered as more and more countries face severe water shortages.

NEIK also see significant potential in the field of Counter Insurgency (COIN), and management is exploring future possibilities in this sector. In particular, NEIK’s intention for the future is to develop a “Surveillance Aircraft,” as the requirements for it are similar to those of its subsidiary NSEL’s commercial versions.

Based on the commercial versions, the Surveillance aircraft would be able to fly very low, away from radar detection. NSEL’s plane would be light (20% less than its main competition) with the same engine and power, and would be able to carry +1,500 kg of equipment. It would be the least expensive airplane to operate and it has excellent performance capabilities. Its landing gear would allow the airplane to land on improvised runways, which is excellent for surveillance in remote areas with no infrastructure.

Management will continue to explore the Surveillance opportunity with the intent of taking action on it, once the “Agriculture and RRFFF” versions are well established in the marketplace.
Once agreements are signed-off with the international aerospace company and its subsidiary for the worldwide rights, the Company has plans to move forward, in marketing the airplanes, establishing additional infrastructure, securing pre-production orders, and expanding MRO capability, among other activities.

For further information about this news release contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and

About Northstar Electronics, Inc.

Northstar Electronics, Inc. (OTCQB:NEIK),established in the late 1990’s, carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts, Northstar has moved towards making and selling its own independent systems –

Safe Harbor Statement:
This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

Predictive Technology Group, Inc.’s (PRED) Subsidiary Provides a Sponsorship at 4th Annual Perinatal Stem Cell Society Congress

Salt Lake City, UT- March 5, 2018- Predictive Biotech, Inc., a wholly owned subsidiary of Predictive Technology Group, Inc. (PRED.OTCPINK) provided a sponsorship at the 4th Annual Perinatal Stem Cell Society Congress, Salt Lake City, UT on March 1-2, 2018.

In 2013, the Perinatal Stem Cell Society, Inc. a non-profit organization was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders. Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/Wharton’s jelly, as well as placental blood and placental tissue

Dr. Doug Schmid, Chief Science and Lab Officer, at Predictive Biotech, Inc., presented an oral presentation to the society titled: “Wharton’s Jelly: A Perinatal Cytokine Reservoir?”

Dr. Schmid received his Ph.D. in Physiology from the University of Utah School of Medicine in Salt Lake City, Utah. He completed four years of post-doctoral training at the University of Utah Medical School and five years as a Research Associate at the University of Utah Medical School as a cellular biologist. Dr. Schmid has 23 years of experience in primary cell culture, tissue processing and cryogenic storage of cells and tissues. After working at the University of Utah, from 2009 to present, Dr. Schmid has established, implemented, and supervised the operational aspects of several tissue companies, including the recovery, quality control, processing, and distribution of tissue. He is passionate about quality and vitality of physiological products and the vast benefits they deliver.

Predictive Technology Group, Inc. wholly owned subsidiary, Predictive Biotech, Inc. is in the business of developing advancements in human cell and tissue products. Data collected in collaboration with other research institutes and clients are the cornerstone in Predictive Biotech’s product development.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively,,, and

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.